Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Analysis of Biofilm Mediated Fouling of Nanofiltration Membranes (AFFIRM)

Framework: FP7 — Ideas
Programme: European Research Council
Theme: European research council
Destination: Starting grants
Action type: Support for frontier research (ERC)
Panel: Products and process engineering
Countries involved: Ireland
Call:  (ERC-2011-StG_20101014, 2011)
Start date: 2011-10-01
End date: 2016-09-30
Duration (months): 60.0
Total project cost (EUR): 1468986.56
EU funding (EUR): 1468986.56
Participants: 1
Project status: CLOSED

1.2 billion people worldwide lack access to safe drinking water. Drinking water quality is threatened by newly emerging organic micro-pollutants (pesticides, pharmaceuticals, industrial chemicals) in source waters. Nanofiltration is a technology that is expected to play a key role in future water treatment processes due to its effectiveness in removal of micropollutants. However, the loss of membrane flux due to fouling is one of the main impediments in the development of membrane processes for use in drinking water treatment. Currently there is a wholly inadequate mechanistic understanding of the role of biofilm on the fouling of nanofiltration membranes. Applying techniques including confocal microscopy, force spectroscopy, and infrared spectroscopy using an experimental programme informed by a technique known as scale-down together with mathematical modelling, it is confidently expected that significant advances will be gained in the mechanistic understanding of nanofiltration biofouling. The specific objectives are 1. How is the rate of formation and extent of such biofilms influenced by the biological response to the local microenvironment? 2 Elucidate the effect of extracellular polysaccharide substances on physical properties, composition and structure of these biofilms. 3: Investigate mechanisms to enhance biofilm removal by a physical detachment process complemented by techniques that alter biofilm material properties. A more fundamental insight into the mechanisms of nanofiltration operation will help in further development of this treatment method in future water treatment processes.

Keywords: biofilm,biofouling,nanofiltration,membrane,water
Methods for high-throughput (HTP) analysis of protein glycosylation (HIGHGLYCAN)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Netherlands,United Kingdom,Germany,Ireland,Croatia,Slovenia,United Kingdom,France,Germany
Call:  (FP7-HEALTH-2011-two-stage, 2011)
Start date: 2011-11-01
End date: 2016-10-31
Duration (months): 60.0
Total project cost (EUR): 7799296.87
EU funding (EUR): 5998972.4
Participants: 9
Project status: CLOSED

Glycosylation is a post-translational modification that enriches protein complexity and function. Dysregulation of glycosylation is associated with a wide range of diseases, including cancer, diabetes, as well as congenital, cardiovascular, immunological and infectious disorders. A number of studies identified potentially important glycan disease biomarkers. With regard to biotechnology, proper glycosylation of biologicals is important, as deviations in glycosylation are known to be associated with adverse drug reactions and reduced therapeutic efficacy. However, glycomics is significantly lagging behind genomics and proteomics, mainly due to the absence of high-throughput analytical methods which can reliably quantify a multitude of glycan structures in complex biological samples. We are confident that by coordinated efforts of leading European scientists in glycan analysis using HPLC, MS and CGE-LIF technologies this project will make a decisive step forward by developing real high-throughput tools for glycosylation analysis. By teaming up with leading European researchers in the field of genome wide association studies this project will perform validation of all methods on extremely well characterized set of samples resulting from the FP6 EuroSpan project. The addition of the newly generated glycome data to the pre-existing information about these individuals will enable development of methods for the systems biology approach analysis of the glycome which will integrate glycomic, genomic and environmental data about thousands of individuals. The same methods will also be adapted for quality control and monitoring in the production of biopharmaceuticals. Strong participation of SMEs in the project and close contacts with large industrial partners will ensure that research accomplishments achieved by collaboration between academic and industrial scientists are swiftly transformed into innovative products and services for the benefit of European industry.

Keywords: n-glycan,biologicals,biotechnology,biomarker discovery
Quantum-coherent drive of energy transfer along helical structures by polarized light (QUENTRHEL)

Framework: FP7 — Ideas
Programme: European Research Council
Theme: European research council
Destination: Starting grants
Action type: Support for frontier research (ERC)
Panel: Physical and Analytical Chemical sciences
Countries involved: Italy
Call:  (ERC-2011-StG_20101014, 2011)
Start date: 2012-03-01
End date: 2018-02-28
Duration (months): 72.0
Total project cost (EUR): 1479480.0
EU funding (EUR): 1479480.0
Participants: 1
Project status: CLOSED

Electronic energy transfer (EET) is a ubiquitous photophysical process that plays a crucial role in the light-harvesting capabilities of natural antenna complexes. Emerging experimental breakthroughs indicate that the dynamics of light harvesting is not fully described by a classical random-walk picture, but also quantum coherent transfer takes place. Interestingly, coherent EET processes were recently detected also in a conjugated polymer at room temperature, suggesting that coherent EET may play a key role in artiﬁcial systems, as well. This suggests a new way to think about the design of future artificial photosynthetic systems and can potentially open a revolutionary avenue for the effective use of biological systems and conjugated polymers as quantum devices or resources for quantum information processing. The main goal of the project is to give an important contribution in this breakthrough field, looking for a piece of information still missing: the possible presence of a relation between structure and coherent mechanisms. The main challenge is to develop new spectroscopic tools able to unveil the presence and the nature of vibrational modes acting during the energy migration and possibly driving coherent mechanisms. To this aim, a new 2D technique is proposed, which merges together the sensitivity of circular dichroism to structural deformations and the power of 2D photon echo in detecting coherent effects. Instead of natural light-harvesting antennae, the objects of this project will be model systems, more stable and easier to manipulate and modify ad hoc. The attention will be mainly focused on multichromophoric systems with helical arrangements because they mimic a ubiquitous motif that nature exploited to develop highly efficient EET. The helical core can act indeed as a wire, directionally driving the energy migration and, perhaps, preserving long-lived coherences.

Keywords: quantum computing,coherent energy transfer,chiral multichromophoric systems,2d electronic spectroscopy
Developmental Origins of Healthy and Unhealthy Ageing: The Role of Maternal Obesity (DORIAN)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Italy,Finland,United Kingdom,Germany,Spain,United Kingdom,Belgium
Call:  (FP7-HEALTH-2011-two-stage, 2011)
Start date: 2012-01-01
End date: 2014-12-31
Duration (months): 36.0
Total project cost (EUR): 3863873.8
EU funding (EUR): 2999973.0
Participants: 10
Project status: CLOSED

Europe has the highest proportion of elderly people in the world. Cardiovascular disease (CVD), type 2 diabetes (T2D), sarcopenia and cognitive decline frequently coexist in the same aged individual, sharing common early risk factors and being mutually reinforcing. Obesity is a main health concern in the world. In the EU one-third of women of reproductive age are overweight and 20% are obese, a prevalence predicted to double in the next decade. There is growing evidence that maternal obesity increases the long term risk of CVD, T2D and neurodegenerative morbidity in the offspring. This project will clarify if and to what extent maternal obesity leads to premature and unhealthy ageing, by causing early, i.e. pre-/perinatal metabolic and genetic vulnerability, starting from insulin resistance and glucocorticoid exposure, leading to oxidative-stress, telomere/DNA damage, epigenetic changes, interacting with genetic and environmental variability, resulting in altered gene expression/repair, and ultimately in disease during life and pathological ageing. We will investigate the postulated mechanisms during pregnancy and development, their life long consequences in animal models and in large human cohorts followed from prenatal life until ageing, and the possibility to intervene when the condition is still reversible. Surrogate markers to estimate early risk and monitor progression-regression will be defined. This project will comprehensively address the expected impacts listed in the work programme HEALTH.2011.2.2.2-2 targeting the improvement of health and healthy ageing of a broad/broadening European population. The participation of a research intensive SME and European NGOs guarantees success in biomarker discovery-innovation and in dissemination-public preventive programs. The scientific excellence and complementariness of the partners and the relevance of the target health problem will make a highly significant impact on the European policy and research in this area.

Keywords: obesity,fetal programming,frailty,ageing,chronic non communicable disease,insulin resistance,oxidative stress,glucocorticoid excess,epigenetics,candidate genes,telomere length,dna damage
Genome-based biomarkers leading to validated molecular diagnostic tests for response prediction in breast cancer (RESPONSIFY)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Germany,France,Belgium,United Kingdom,Belgium,France,Switzerland,Sweden,Germany,Germany
Call:  (FP7-HEALTH-2011-two-stage, 2011)
Start date: 2012-02-01
End date: 2015-01-31
Duration (months): 36.0
Total project cost (EUR): 7782794.13
EU funding (EUR): 5990194.6
Participants: 12
Project status: CLOSED

Individualisation of cancer therapy based on standardized biomarker assays is one of the most demanding challenges in cancer medicine. In the RESPONSIFY consortium, we will integrate information on response prediction from different breast cancer types and methodologies into biomarker tests for targeted therapies in the clinical routine setting. Those tests will be developed for commercialisation using the expertise of the involved SMEs and industrial partners. To reach this aim, we will use different genome based strategies to identify and characterise new biomarkers as well as validate biomarkers from previous projects. Genome based strategies include new molecular techniques such as genome wide next generation sequencing, epigenetics, gene and exon expression analysis, as well as kinome arrays, in-situ proteomics and quantitative PCR using FFPE tissue. A clearly defined marker finding-training-validation-approach will be the backbone of RESPONSIFY to reach a high level of evidence for commercial diagnostic tests. The established therapy stratification criteria will be further validated within clinical trials using the expertise of the clinical study groups. The clinical study group will develop a web-based data integration and processing system to standardise integration of clinical trial data and biomarker results in one system which will be further used for clinical biomarker driven trials. Health economic characteristics of combined testing and treatment strategies will be determined to inform decision makers, using state-of-the-art cost-utility analysis. Optimising the use of current therapy options and avoiding treatments patients will predictably not respond to, may improve cost-utility parameters to levels acceptable for most health systems. For rapid evaluation of response parameters, the major focus will be on neoadjuvant therapy. The RESPONSIFY project will lead to validated tests based on formalin-fixed paraffin embedded tissue to predict resistance

Keywords: anti her2 and antiangiogenic therapy,breast cancer,genome wide next generation sequencing,epigenetics,gene / exon expression analysis,kinome arrays,in-situ proteomics,quantitative pcr,ffpe
From pebbles to planets: towards new horizons in the formation of planets (PEBBLE2PLANET)

Framework: FP7 — Ideas
Programme: European Research Council
Theme: European research council
Destination: Starting grants
Action type: Support for frontier research (ERC)
Panel: Universe sciences
Countries involved: Sweden
Call:  (ERC-2011-StG_20101014, 2011)
Start date: 2012-01-01
End date: 2016-12-31
Duration (months): 60.0
Total project cost (EUR): 1332467.0
EU funding (EUR): 1332467.0
Participants: 1
Project status: CLOSED

The goal of this ERC Starting Grant proposal is to make significant advances in our understanding of how planetesimals and gas giant planets form. I propose an ambitious research programme dedicated to answering three key questions at the frontier of planet formation theory: - How do mm-sized particles grow past the bouncing barrier? - What is the Initial Mass Function of planetesimals? - How do the cores of gas giants form and evolve?} I will address these questions using a combination of novel ideas and computer simulations to model three critical stages of planet formation: 1) the growth of pebbles into rocks and boulders by coagulation and vapour condensation, 2) the gravitational collapse of clumps of rocks and boulders into planetesimals with an array of sizes, and 3) the long term growth of planetesimals as they grow to become cores of gas giants by accreting pebbles embedded in the gas. These investigations will form an important theoretical foundation for understanding the next generation of observations of protoplanetary disc pebbles, planetesimal belts, and planetary systems. The self-consistent models for the formation of planets resulting from this proposal will shed light on the spatial distribution of pebbles in gas discs around young stars (observable with the ALMA telescopes), on the initial state of planetesimal belts (crucial for understanding the evolution of debris discs observable with JWST and the asteroid and Kuiper belts), and on the formation and evolution of the wealth of exoplanetary systems detected in the near future (by astrometry with the Gaia satellite, by ground-based radial velocity surveys, and by direct imaging with E-ELT).

Keywords: exoplanets,planet formation,protoplanetary discs,dust growth,planetesimals,gas giants
Atomically precise nanoelectronic materials (PRECISE-NANO)

Framework: FP7 — Ideas
Programme: European Research Council
Theme: European research council
Destination: Starting grants
Action type: Support for frontier research (ERC)
Panel: Condensed matter physics
Countries involved: Finland
Call:  (ERC-2011-StG_20101014, 2011)
Start date: 2012-02-01
End date: 2017-01-31
Duration (months): 60.0
Total project cost (EUR): 1494447.6
EU funding (EUR): 1494447.6
Participants: 1
Project status: CLOSED

The current devices used in electronics have reached nanometre dimensions where the precise nature and location of every atom matters. To further drive the development of existing technologies and to test proposals for next generation nanoelectronics, we need tools that allow structural and electronic characterization of materials down to the atomic scale. We need to be able to measure the position and nature of the atoms, as well as the local density of electronic states at a specific energy, the charge distribution, and atomic scale magnetic properties. In addition, we need methods that allow controlled manipulation of the relevant atomic-scale details of the active region of the material, where we could pick and place atoms or molecules and create vacancies at pre-defined locations. The goal of this project is to develop such tools and apply them to three different materials systems of enormous current interest: nanostructured graphene, molecular networks and topological insulators. Progress towards using these materials in real life electronic applications is currently limited by the restricted experimental handle of their structure at the atomic scale: for example, edge structure in graphene nanostructures and contacts in molecular devices. I will use scanning probe techniques to fabricate nanoelectronic devices of atomically precise structure and explore the possibilities offered by well-defined nanostructures and spatially controlled charge and spin-doping.

Keywords: scanning probe techniques,graphene nanostructures,molecular networks,topological insulators
European multicentre, randomised, phase III clinical trial of hypothermia plus best medical treatment versus best medical treatment alone for acute ischaemic stroke (EUROHYP-1)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Germany,Germany,Denmark,United Kingdom,Germany,Netherlands,Germany,Italy,United Kingdom,Sweden,Poland,France,United Kingdom,Spain,Germany,France,Finland,France,Germany,Türkiye,Greece,Lithuania,Estonia,Austria,Belgium,Belgium,Austria,United Kingdom,United Kingdom,Australia
Call:  (FP7-HEALTH-2011-two-stage, 2011)
Start date: 2012-02-01
End date: 2018-07-31
Duration (months): 78.0
Total project cost (EUR): 11740832.37
EU funding (EUR): 8081665.4
Participants: 40
Project status: CLOSED

The consortium led by UKER and EuroHYP, the European Stroke Research Network for Hypothermia, proposes a large, multicentre clinical trial which will assess mild hypothermia as a novel treatment for ischemic stroke. Stroke is the second cause of death world-wide and the second cause of lost disability-adjusted life years in high-income countries. Stroke incidence rises exponentially with age, so its social and economic burden will grow with the ageing of the European population. Current treatment options for the 80 to 85% of all strokes due to cerebral ischaemia - around. 900,000 events in Europe every year, or one every 40 seconds - are extremely limited. Systematic review of experimental studies suggests that hypothermia is the most promising intervention identified to date. Therapeutic cooling is effective in reducing ischaemic brain injury following cardiac arrest, and hypothermia is therefore considered by experts the most promising treatment for patients with acute ischaemic stroke, next to reperfusion strategies. The EuroHYP-1 trial is a pan-European, open, randomised, phase III clinical trial which will assess the benefit or harm of therapeutic cooling in 800 awake adult patients with acute ischaemic stroke. In addition to efficacy and safety, the economic impact of therapeutic hypothermia will be assessed, along with several sub-studies involving imaging, ultrasound, and biomarker methods. The investigators involved in the EuroHYP-1 consortium are leading European experts in statistical design and analysis, therapeutic hypothermia, imaging, health economics, ultrasound, biomarkers, and trial execution (implementation and monitoring). Moreover – in addition to these academic experts the consortium also involves European patient and family advocacy groups and small and medium-sized enterprises, and the joint endeavours of this extended team will ensure the successful enrolment of patients at fifty hospitals across 15 countries in Europe.

Keywords: therapeutic hypothermia,ischaemic stroke,phase iii trial,health economic assessment,patient-reported outcomes,quality of life,industrial collaboration,technological innovation
European Clinical trials in Rare Sarcomas within an integrated translational trial network (EUROSARC)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: France,Netherlands,France,United Kingdom,Italy,France,Spain,Poland,Germany,Spain,Belgium,United Kingdom,Spain,Germany,Germany,Spain
Call:  (FP7-HEALTH-2011-two-stage, 2011)
Start date: 2011-12-01
End date: 2018-05-31
Duration (months): 78.0
Total project cost (EUR): 7885914.25
EU funding (EUR): 5953832.0
Participants: 20
Project status: CLOSED

Sarcomas are rare malignant tumors, with an overall incidence of 6/105/year. Bone and soft tissue connective tissue tumours encompass more than 50 different rare histotypes and more than 150 different molecular subtypes. The incidence of individual rare sarcomas subtypes is often less than 0.5/105/year. Given sarcoma rarity as a group, but even more as individual entities, few prospective clinical trials testing local or systemic treatments have been performed in specific subtypes of sarcomas. Clinical trials in specific histological and molecular subtypes of sarcoma can only be performed through integrated clinical networks, centres of clinical excellence, supported by translational analysis. The drive for EUROSARC comes from the fact that sarcomas should now receive treatment adapted to histological and molecular subtypes and are ideal models to develop rational oncogene-targeted therapies. Trials based on selected molecular subtypes should now represent the standard approach to delineate novel treatments in individual disease subsets. They are also potential proof of concepts for first-in-class targeted treatment. EUROSARC aims at validating 1) novel local and systemic treatment strategies in localized phase, and 2) innovative targeted therapies in advanced phase based on the scientific understanding of molecular alterations driving the tumours thereby developing paradigm changing clinical research. The consortium builds on the successful co-ordination of scientific excellence of Conticanet and EuroBoNeT FP6 NoEs, where most partners were involved. The objective will be achieved through the development and conduct of 9 (2“Soft tissues” + 7“Bones”, 9 phase I/II and III) investigator-driven clinical trials in rare histological and molecular subtypes of sarcoma, through the establishment of an integrated consortium, gathering representatives of most European sarcoma groups, SME, all with proven track records of scientific and clinical excellence.

Keywords: sarcoma,rare histological and molecular subtypes,soft tissues + bone tumours,molecular diagnosis,targeted therapies+novel agents,local treatment strategies,hystotype specific neoadjuvant therapy